NEW YORK, Feb. 11, 2016 /PRNewswire/ -- Bioethics
International, a not-for-profit organization focused on the ethics
and governance of how medicines are researched, developed, marketed
and made accessible to patients around the world, today announced
that the editors of BMJ Open had named the publication of
the Good Pharma Scorecard an 'Editors' Pick' for 2015. The
publication is also featured as one of BMJ Open's 'Most
Popular Articles', which includes those published in the last year
that are most frequently read.
"In December we surveyed our staff editors, who oversee and
manage the peer review process, to tell us about their favourite
articles from 2015," wrote Ed
Sucksmith, assistant editor of BMJ Open, in a BMJ
Open blog post. "In our second editors' pick, Jennifer Miller and colleagues examined the
levels of clinical trial registration, reporting and publication
rates for new drugs approved by the Food and Drug Administration
(FDA) in 2012."
The study sought to evaluate clinical trial registration,
reporting and publication rates for 15 new drugs approved by the
FDA in 2012 by both legal requirements, as established by the 2007
U.S. Food and Drug Administration Amendments Act (FDAAA), and the
ethical standard that all human subject research should be publicly
accessible to contribute to generalizable knowledge. Wide variation
in practices among drugs and their sponsors was observed.
"We appreciate BMJ Open's support of clinical trial
transparency and commitment to making research publicly available.
Clinical trial transparency is important for advancing patient and
global public health," said Jennifer E.
Miller, Ph.D., president of Bioethics International,
assistant professor of medical ethics in the Department of
Population Health at NYU Langone Medical Center. "Following the
interest we've had in the Good Pharma Scorecard, we remain focused
on releasing the next set of rankings later this year."
About the Good Pharma Scorecard
The Good Pharma Scorecard measures and ranks pharmaceutical
companies and new medicines and vaccines on key ethics, human
rights & population health performance indicators. We focus on
the ethical issues that impact patients the most. Our first
scorecard ranks companies and new drugs on their clinical trial
transparency, according to both legal and ethics standards. To see
scores and data, please visit: Transparency
Index | Legal Compliance Index.
About Bioethics International
Bioethics International's (BEI) mission is to empower
professionals and organizations in healthcare, life science and
biotechnology to make responsible decisions – on issues that impact
patients the most. Currently, we focus on the ethics and governance
of how medicines are researched, developed, marketed and made
accessible to patients around the world. For more information,
please visit www.bioethicsinternational.org.
Media Contacts
Tony Russo, Ph.D., or
Lena Evans
Russo Partners, LLC
212-845-4251
212-845-4262
tony.russo@russopartnersllc.com
lena.evans@russopartnersllc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioethics-internationals-good-pharma-scorecard-publication-selected-as-bmj-open-editors-pick-for-2015-300218458.html
SOURCE Bioethics International